The report of a new class of potent and highly selective inhibitors of Bcr-abl highlights the potential for a truly leukemia-specific drug with no expected off-target activity. GNF-2, as a representative compound of this class, may have inspired the identification of a region of Bcr-abl that is amenable to drug design, just as imatinib did almost a decade ago.
- Jeffrey F Ohren
- Judith S Sebolt-Leopold
